India's Indus Biotech to Initiate Clinical Trials for Anti-HIV and Anti-Swine Flu Molecules

Strategic Insights -

India's Indus Biotech is set to initiate Phase I clinical trials for its anti-HIV and anti-swine flu molecules in the next 3-4 months. The company has filed an investigative new drug (IND) application for its anti-HIV drug with the US FDA and has received approval to conduct Phase I clinical trials in the US. Indus Biotech is also in discussions with multinational drug makers for outlicensing its new molecules and has been approached by several MNCs for this purpose.

Key Takeaways:

  • Indus Biotech is working on 12 major diseases and has two molecules in advanced stages for the treatment of HIV and Swine Flu, with Phase I clinical trials to begin in the next 3-4 months.
  • The company has filed an IND application for its anti-HIV drug with the US FDA and has received approval to conduct Phase I clinical trials in the US.
  • Indus Biotech has filed an application with the Drug Controller General of India for its anti-HINI drug and has been assured that the matter will be fast-tracked.
  • The company is in talks with multinational drug makers for outlicensing the new molecules, with several MNCs already approaching Indus Biotech for this purpose.
  • Phase I trials are the first human exposure to a new molecule, aimed at determining its safety and assessing its effects in a small group of people.
  • Outlicensing the new molecules to multinational companies will allow Indus Biotech to focus on its core areas of research and development, while also generating revenue.

Statistics:

  • 12 major diseases: The number of diseases that Indus Biotech is working on.
  • 2 molecules: The number of molecules in advanced stages for the treatment of HIV and Swine Flu.
  • 3-4 months: The timeframe for Indus Biotech to initiate Phase I clinical trials.
  • 1: The number of IND application filed by Indus Biotech with the US FDA for its anti-HIV drug.
  • 1: The number of Phase I clinical trials approved by the US FDA for Indus Biotech's anti-HIV drug.
  • 1: The number of applications filed by Indus Biotech with the Drug Controller General of India for its anti-HINI drug.

Sources:

  • Asia Pulse: Dec 24
  • Indus Biotech: Managing Director Sunil Bhaskaran (no date)
  • PTI (Press Trust of India): cg 24-12 1020 (no date)